Skip to main content

Table 4 Association between CPA4 variants and advanced prostate cancer

From: Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer

SNP

Genotype

Cases, n (%)

Controls, n (%)

Odds Ratio

(95% CI)*

p-value

rs901799

CC

363 (71.7)

372 (73.5)

1

 
 

CA

131 (2.6)

121(23.9)

1.11 (0.83 – 1.48)

0.46

 

AA

12 (2.4)

13 (2.6)

0.95 (0.43 – 2.1)

0.90

rs3807344

AA

213 (42.1)

201 (39.7)

1

 
 

AG

221 (43.7)

244 (48.2)

0.85 (0.66 – 1.11)

0.25

 

GG

72 (14.2)

61 (12.1)

1.11 (0.75 – 1.65)

0.59

rs1569132

AA

172 (34.0)

165 (32.6)

1

 
 

AG

234 (46.2)

252 (49.8)

0.89 (0.67 – 1.18)

0.41

 

GG

100 (19.8)

89 (17.6)

1.08 (0.75 – 1.54)

0.68

rs1038628

GG

209 (41.3)

212 (41.9)

1

 
 

GT

220 (43.5)

221 (43.7)

1.01 (0.77 – 1.33)

0.94

 

TT

77 (15.2)

73 (14.4)

1.07 (0.73 – 1.57)

0.78

rs2171492

GG

216 (42.7)

212 (41.9)

1

 
 

GT

216 (42.7)

233 (46.0)

0.91 (0.7 – 1.19)

0.49

 

TT

74 (14.6)

61 (12.1)

1.19 (0.8 – 1.77)

0.38

rs1488009

AA

402 (79.4)

387(76.5)

1

 
 

AG

93 (18.4)

114 (22.5)

0.78 (0.57 – 1.07)

0.12

 

GG

11 (2.2)

5 (0.01)

2.12 (0.73 – 6.16)

0.17

  1. * From unconditional logistic regression model, adjusted for age, ethnicity, and medical institution.